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The Journal of Immunology
Calcium-Sensing Receptor Autoantibodies in Patients with
Autoimmune Polyendocrine Syndrome Type 1: Epitopes,
Specificity, Functional Affinity, IgG Subclass, and Effects on
Receptor Activity
Mahmoud Habibullah,*,1 Julie A. Porter,* Nicolas Kluger,† Annamari Ranki,†
Kai J. E. Krohn,‡ Maria L. Brandi,x Edward M. Brown,{ Anthony P. Weetman,* and
E. Helen Kemp*
A major manifestation of autoimmune polyendocrine syndrome type 1 (APS1) is hypoparathyroidism, which is suggested to result
from aberrant immune responses against the parathyroid glands. The calcium-sensing receptor (CaSR), which plays a pivotal role in
maintaining calcium homeostasis by sensing blood calcium levels and regulating release of parathyroid hormone (PTH), is an au-
toantibody target in APS1. In this study, the aim was to characterize the binding sites, specificity, functional affinity, IgG subclass,
and functional effects of CaSR autoantibodies using phage-display technology, ELISA, and bioassays. The results indicated that
CaSR autoantibody binding sites were at aa 41–69, 114–126, 171–195, and 260–340 in the extracellular domain of the receptor.
Autoantibodies against CaSR epitopes 41–69, 171–195, and 260–340 were exclusively of the IgG1 subclass. Autoantibody responses
against CaSR epitope 114–126 were predominantly of the IgG1 with a minority of the IgG3 subclass. Only autoantibodies
recognizing CaSR epitopes 114–126 and 171–195 affected receptor activity; inositol-phosphate accumulation was increased
significantly in HEK293-CaSR cells, and PTH secretion from PTH-C1 cells was reduced significantly when either were incubated
with purified Ab and Ca2+ compared with Ca2+ alone. In conclusion, although the majority of APS1 patients do not have
CaSR-stimulating autoantibodies, the hypoparathyroid state in a small minority of patients is the result of functional
suppression of the parathyroid glands. The Journal of Immunology, 2018, 201: 000–000.
H
ypoparathyroidism is a major manifestation of autoim-
mune polyendocrine syndrome type 1 (APS1; 240300)
and is believed to result from aberrant immune responses
against the parathyroid glands (1). Two parathyroid autoantigens
have been defined so far in APS1: the calcium-sensing receptor
(CaSR) and NACHT leucine-rich-repeat protein 5 (NALP5). CaSR
autoantibodies have been identified in up to 86% of APS1 patients
and have also been detected in some patients with idiopathic
hypoparathyroidism (2–5). In contrast, NALP5 autoantibodies
appear to be confined to patients with APS1, with a frequency of
30–40% (6, 7).
The CaSR has a central role in controlling parathyroid hormone
(PTH) secretion in response to changes in extracellular calcium
concentration (8). In some patients, CaSR autoantibodies that
affect the functional activity of the receptor have been identified;
CaSR-specific IgG from patients with PTH-dependent hypercal-
cemia have been shown in vitro to inhibit Ca2+-stimulated phos-
phorylation of ERK1/2 and accumulation of inositol phosphates and
to increase PTH release from cultured parathyroid cells (9–12).
Such blocking autoantibodies may inhibit CaSR signaling and cause
secretion of PTH from the parathyroid even under conditions in
which serum calcium is high (10). In contrast, two patients each
with idiopathic hypoparathyroidism and APS1 with hypoparathy-
roidism have been identified with CaSR autoantibodies, which
stimulate receptor activity in vitro; it is possible that such effects
in vivo could result in abnormally low PTH levels, even when
blood calcium levels are low (13, 14).
Although the presence of CaSR autoantibodies is compelling
evidence of an autoimmune process directed against the para-
thyroid glands in APS1, the actual pathogenesis of hypoparathy-
roidism remains unclear. At least occasional patients appear to have
autoantibodies with functional activity that could lead to sup-
pression of the parathyroid gland function rather than their irre-
versible destruction (14). Additionally, although never analyzed,
CaSR autoantibodies could destroy parathyroid cells through Ab-
dependent cellular cytotoxicity or through complement fixation;
Brandi et al. (15) demonstrated Ab-mediated cytotoxicity against
cultured bovine parathyroid cells when exposed to serum from
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patients with idiopathic hypoparathyroidism, although the autoantigen
responsible was not identified. To understand more fully the potential
role for CaSR autoantibodies in APS1, the aim of the current study
was to characterize the specificity, functional affinity, IgG subclass,
and effects on CaSR activity of CaSR autoantibodies in relation to
their epitopes.
Materials and Methods
Participants
The Medical Ethics Committee of Helsinki University Central Hospital
approved the study, which was performed in accordance with the Decla-
ration of Helsinki. Informed written consent was obtained from all par-
ticipants or their parents prior to inclusion in the study. The 16 APS1
patients were unrelated and were positive for autoantibodies against the
CaSR (7). The demographic, clinical, AIRE gene mutations, and autoan-
tibody profile of the patients are summarized in Supplemental Table I.
Sixteen healthy blood donors to the Finnish Red Cross Blood Service, who
had no clinical signs or a family history of APS1 or of any other auto-
immune disease, served as controls (7). Serum samples obtained from
participants were stored at 280˚C.
IgG purification
IgGwas isolated from sera using protein G Sepharose 4 Fast Flow (Amersham
Biosciences, Uppsala, Sweden) affinity chromatography, according to the
manufacturer’s instructions. IgG was eluted using 0.2 M glycine hydro-
chloride (pH 3), and the collected 1-ml fractions were neutralized with 50 ml
of 1 M Tris base (pH 9). Fractions containing IgG, as determined by pho-
tometry at 280 nm, were dialyzed against PBS (pH 7.4) and concentrated
using an Amicon Concentrator (Amicon, Beverly, MA). IgG samples were
sterilized with a Millex Filter Unit (MilliporeSigma, Bedford, MA) and
stored at 10 mg/ml at –20˚C.
Phage-display panning experiments
The preparation of the CaSR peptide phage-display library has been de-
scribed elsewhere (16). For panning experiments, a 10-ml aliquot of patient
or control IgG was applied to the well of a 96-well microtiter plate in 50 ml
of buffer containing 1.5 mM sodium carbonate and 3.5 mM sodium hy-
drogen carbonate. Plates were incubated at room temperature for 2 h be-
fore washing with PBS/0.05% (w/v) Tween 20 (PBS/Tween). To block any
nonspecific phage binding, 400 ml of 2% BSA in PBS was added to the
wells, and incubation at room temperature continued for 2 h. The wells
were rinsed again with PBS/Tween before the addition of a 100-ml sample
of phage-display library containing an estimated 1 3 1010 phages. Plates
were incubated overnight at 4˚C to allow the interaction of CaSR Abs, with
peptides displayed on the surface of the phage particles. The wells were
washed extensively with PBS/Tween to remove unbound phage. Bound
phage were then eluted with 150 ml of 100 mM hydrochloric acid (adjusted
to pH 2.2 with glycine) and then neutralized with 9 ml of 2 M Tris base.
The phage suspension was subsequently used to infect 2 ml of exponen-
tially growing Escherichia coli XL1 Blue MRF9 (Agilent Technologies,
Wokingham, U.K.) for 15 min at room temperature. Aliquots of the in-
fected cells were then plated onto Luria–Bertani (LB) agar containing
10 mg/ml tetracycline and 100 mg/ml ampicillin, and the plates were in-
cubated overnight at 37˚C. This allowed the assessment of the total number
of eluted phage in each round of panning.
To generate a phage-display library for the next round of panning, the
E. coli XL1 Blue MRF9 culture infected with eluted phage was made up to
10 ml with LB medium and incubated for 1 h with shaking at 37˚C before
superinfection with of 1 3 1011 PFUs of VCSM13 helper phage (Agilent
Technologies). Following incubation at room temperature for 30 min, the
cells were transferred to 100 ml of LB medium containing 10 mg/ml tet-
racycline, 100 mg/ml ampicillin, and 10 mg/ml kanamycin and grown
overnight with shaking at 37˚C. The 100-ml culture was centrifuged at
2000 3 g for 15 min. Phage particles were precipitated from the super-
natant by addition of polyethylene glycol 4000 to 6% and sodium chloride
to 750 mM. Following overnight incubation at 4˚C, phage were harvested
by centrifugation at 2000 3 g for 30 min, and the pellet was resuspended
in 1–2 ml of PBS before storage at 280˚C. This first round phage-display
library was used in a second round of panning. In all, five rounds of
panning were undertaken for each IgG sample.
After the fifth round of panning, plasmid DNA was prepared from
randomly selected bacterial clones using a Wizard Plus SVMinipreps DNA
Purification System (Promega, Southampton, U.K.). Sequencing using a
pComb3-specific primer pc3prim1 (59-GGTGGCGGCCGCAAATTC-39)
(Eurofins Genetic Services, London, U.K.) with a BigDye Terminator
Version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA),
and an ABI 3730 capillary sequencer (Applied Biosystems) was used to
identify cloned CaSR DNA fragments. The latter were analyzed and trans-
lated using Lasergene Core Suite sequence analysis software (DNASTAR,
Madison, WI). The EMBOSS Pairwise Sequence Alignment tool provided as
part of the European Bioinformatics Institute–European Molecular Biology
Laboratory bioinformatics services (www.ebi.ac.uk) (Cambridge, U.K.) was
used to locate the CaSR peptide sequences on the full-length receptor.
CaSR peptide ELISAs
CaSR peptide ELISAs were used to verify the binding of CaSR autoan-
tibodies to identified CaSR epitopes, as detailed previously (16). The
synthetic peptides (Cambridge Peptides, Birmingham, U.K.) used are lis-
ted in Supplemental Table II. For ELISAs, the required peptide was diluted
in PBS to 200 ng/ml, and 100-ml samples were used to coat the wells of a
96-well microtiter plate. The plates were then incubated overnight at 4˚C.
Excess peptide was removed by decanting, and the wells were blocked
with blocking buffer (PBS containing 0.1% [w/v] Tween 20 and 3% [w/v]
BSA) for 30 min at 37˚C. Plates were washed four times with washing
buffer (PBS containing 0.1% [v/v] Tween 20). Duplicate 100-ml samples
of sera at a 1:100 dilution in blocking buffer were added to the wells. PBS
was applied as a control to measure any nonspecific binding of ELISA
reagents in the absence of sera. The plates were incubated at room tem-
perature for 1 h and then washed four times with washing buffer. A 100-ml
of goat anti-human IgG conjugated to alkaline phosphatase (Sigma-
Aldrich, Poole, U.K.) diluted to 1:2000 in blocking buffer was added to
each well for 1 h at room temperature. After washing five times with
washing buffer, 100 ml of alkaline phosphatase substrate SIGMAFAST
p-Nitrophenyl phosphate (Sigma-Aldrich) was applied to each well and
plates were incubated at room temperature. A LabSystems Integrated
EIA Management System spectrophotometer (Life Sciences, Basingstoke,
U.K.) was used to read absorption of the wells at 405 nm. All sera were
tested in duplicate, and the mean OD405 value was calculated. Each serum
was tested in three experiments. For each ELISA, the upper limit of normal
was calculated as the mean OD405 + 3 SD of 16 healthy individuals. Sera
with an Ab index above the upper limit of normal were designated as
positive for CaSR autoantibodies against the specific CaSR peptide. For
estimating CaSR autoantibody titers, patient sera were analyzed at dilu-
tions ranging from 1:100 to 1:10,000. Titers were defined as the serum
dilution at which Ab binding could still be detected above the upper limit
of normal for the CaSR peptide ELISA.
CaSR autoantibody purification
Autoantibodies against specific CaSR epitopes were purified using peptide
affinity chromatography. The required CaSR peptides (2 mg) were coupled
to CarboxyLink Columns according to a CarboxyLink Immobilization Kit
(Thermo Fisher Scientific, Waltham, MA). Patient IgG samples were ap-
plied to peptide affinity columns in PBS and eluted in IgG Elution Buffer
(Thermo Fisher Scientific). Samples were dialyzed, concentrated, and
stored as detailed earlier.
Absorption experiments
Absorption experiments were used to evaluate CaSR autoantibody speci-
ficity. Purified CaSR autoantibodies were preabsorbed at a nonsaturating
dilution with a 2003 M excess of the required CaSR peptide and an un-
related control MCHR1 peptide (Alpha Diagnostics, San Antonio, TX).
After incubation at 4˚C for 2 h, samples were centrifuged at 13,0003 g for
15 min, and the preabsorbed Ab was analyzed in duplicate in CaSR peptide
ELISAs alongside nonabsorbed Ab. Ab binding after preabsorption was
expressed as a percentage of Ab binding without preabsorption: 1003
[OD405 in CaSR peptide ELISA after preabsorption of Ab/OD405 in CaSR
peptide ELISAwithout preabsorption of Ab]. All Ab samples were analyzed
in three separate experiments.
IgG subclass ELISAs
To determine the IgG subclass of purified CaSR autoantibodies, anti-human
IgG1, IgG2, IgG3, and IgG4 alkaline phosphatase conjugates (SouthernBiotech,
Birmingham, AL) were applied as the secondary Ab at a 1:2000 dilution in
CaSR peptide ELISAs. All Ab samples were analyzed in three separate
experiments.
CaSR autoantibody functional affinity
To determine functional affinities, purified CaSR autoantibodies were incu-
bated at nonsaturating dilutions with a range of concentrations (0–1000 nM)
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of the required CaSR peptide for 30 min before analysis in the appropriate
CaSR peptide ELISA. Functional affinity was expressed as the concen-
tration of peptide that blocked 50% of Ab binding by reducing the OD405
CaSR peptide ELISA measurement by 50%. All Ab samples were ana-
lyzed in three separate experiments.
Inositol-1-phosphate ELISAs
As detailed previously (14), human embryonic kidney cells expressing the
CaSR (HEK293-CaSR) were plated at 4 3 105 cells per well in 24-well
plates (Nalge Nunc International, Rochester, NY) in 500 ml of DMEM
containing 4.5 g/l glucose, 110 mg/ml sodium pyruvate, 10% FCS, 100 U/ml
penicillin G, 100 mg/ml streptomycin sulfate, and 2 mM L-glutamine (all
from Life Technologies, Paisley, U.K.). Cells were cultured at 37˚C over-
night in a 95% humidified atmosphere of 5% CO2. Cell monolayers were
washed first with serum-free medium and then with stimulation buffer
containing 146 mM sodium chloride, 2.5 mM potassium chloride, 50 mM
lithium chloride, 0.2 mM magnesium chloride, 2.8 mM glucose, and
10 mM HEPES buffer (pH 7.4). Subsequently, HEK293-CaSR cells were
incubated with a 1:100 dilution of purified CaSR autoantibody or control
IgG sample in 100 ml of stimulation buffer or with 100 ml of stimulation
buffer alone. After 10 min at 37˚C, a further 100 ml of stimulation buffer
containing 0, 1.0, 3.0, 6.0, 12.0, or 18.0 mM of calcium chloride was
applied to the cells, and incubation continued for 1 h at 37˚C.
Following incubation, cells were lysed for 30 min at 37˚C with 50 ml of
2.5% IP-One ELISA Kit Lysis Reagent (Cisbio, Gif-sur-Yvette, France).
The accumulation of intracellular IP1 was measured according to an IP-One
ELISA Kit (Cisbio), an immunoassay based on competition between free
IP1 and IP1–HRP conjugate for binding to an anti-IP1 mAb. The results
for IP1 accumulation were expressed as percentage inhibition of IP1–
HRP binding = [1 2 IP1–HRP binding in stimulated cells/IP1–HRP
binding in unstimulated cells] 3 100. Increasing IP1 accumulation in
the HEK293-CaSR cells was reflected by an increase in the percentage
inhibition of IP1–HRP binding. All Ab samples were analyzed in six
separate experiments.
PTH ELISAs
The rat parathyroid epithelial cell line PTH-C1 has been described else-
where (17). Cells were seeded into 24-well plates in Ham’s F-12 Coon’s
Modification Medium (Sigma-Aldrich) containing 10% FCS, 100 U/ml peni-
cillin G, and 100 mg/ml streptomycin sulfate. Once confluent, the cells were
incubated with a 1:100 dilution of purified Ab sample in 500 ml of 1:1
DMEM/Ham’s F-12 Nutrient Mixture (Sigma-Aldrich) or with 500 ml of
medium only. After 10 min at 37˚C, a further 500 ml of containing medium
containing 3.0 mM of calcium chloride was applied to the cells, and in-
cubation continued for 4 h at 37˚C. The cell culture supernatants were
collected and stored at 280˚C. PTH levels in supernatants were measured
in duplicate with a Rat Intact PTH ELISA Kit (Immutopics, San Clemente,
CA), as detailed in the manufacturer’s protocol, and expressed in
picograms per milliliter. All Ab samples were analyzed in six separate
experiments.
Flow cytometry
Flow cytometry was used for the detection of Ab binding to HEK293 CaSR-
GPI cell-surface expressing cells, exactly as previously detailed (4). Briefly,
cells transfected with pcDNA3-CaSR-GPI (4) and untransfected HEK293
cells (as a control) were washed in PBS and treated with Cell Dissociation
Solution (Life Technologies). Cells were then washed with PBS/1% BSA
(PBS/BSA), centrifuged for 5 min at 4˚C, and resuspended in PBS/BSA at
a density of 1 3 107cells/ml. Aliquots of the cell suspension (1 3 106
cells) were transferred to LP4 tubes (Becton Dickinson, Oxford, U.K.) and
then incubated on ice for 15 min before purified CaSR autoantibodies were
added in duplicate to a 1:50 dilution. CaSR autoantibodies preabsorbed
with the relevant CaSR peptide were included as controls. Following in-
cubation on ice for 30 min, cells were washed with 3 ml of cold PBS/BSA
and centrifuged for 5 min at 4˚C. A 5-ml aliquot of FITC-conjugated anti-
human Fab-specific IgG (Sigma-Aldrich) was added to the cells, and the
samples were incubated on ice for 30 min. Cells were then washed twice
and centrifuged before resuspension in 100 ml of PBS/BSA. The mean
fluorescence intensity of each sample was measured using a FACScan
Fluorescence Activated Cell Sorter running CELLQuest acquisition and
analysis software (Becton Dickinson).
Statistical analysis
Statistical analysis was performed by one-way ANOVAwith posttest using
GraphPad Prism software (GraphPad, La Jolla, CA); p values ,0.05 were
considered significant.
Results
CaSR autoantibody binding sites are located in the
extracellular domain
Autoantibodies against the CaSR were demonstrated previously in
16 APS1 patients whose details are summarized in Supplemental
Table I. To identify the receptor binding sites of patient CaSR
autoantibodies, a phage-display methodology was used that employed
a CaSR peptide phage-display library in rounds of selective en-
richment (panning) against individual patient IgG. The number of
eluted phage increased with each panning round, indicating enrich-
ment of IgG-binding CaSR peptides. Following the fifth round of
panning, plasmid DNA was prepared from 50 bacterial clones and
subjected to DNA sequencing to identify the cloned CaSR DNA
fragments and thus the encoded CaSR peptides.
Subsequent analysis of the encoded CaSR sequences indicated
that for each patient there was at least one immunodominant peptide
enriched during the panning procedure. For example, following
alignment, 90% (45/50) of the peptides enriched by IgG from patient
1 contained the CaSR aa 26–71, and 84% (42/50) enriched by
patient 2 IgG included residues 41–71 (Supplemental Table III).
Comparing the immunodominant peptides from this region of
the receptor between all 16 cases identified one potential com-
mon immunodominant epitope at amino acid residues 41–69
(Supplemental Table III). Similar analysis demonstrated two other
common immunodominant epitopes between amino acid residues
114–126 in five cases and between 171–195 in six (Supplemental
Table III). A fourth potential epitope between residues 260–340
was only found in a panning experiment with one patient IgG
(patient 4) (Supplemental Table III). In all cases, the immuno-
dominant peptide sequences were in-frame with respect to both
the PelB leader peptide and the gene III coat protein of the
pComb3 phage-display vector (16). This is imperative for the
correct phage-surface expression of the encoded CaSR peptides.
In panning experiments with IgG from two healthy controls and
two APS1 patients without CaSR autoantibodies, eluted phage
numbers did not increase and no in-frame CaSR immunodominant
peptides were enriched.
To verify further the potential epitopes at amino acid residues
41–69, 114–126, 171–195, and 260–340, sera from patients and
16 healthy controls were analyzed for Ab binding reactivity
in ELISAs using the relevant CaSR peptides (Supplemental
Table II) as the target Ag. The results (Fig. 1) indicated that
the prevalence of CaSR Ab positivity in the patient group was
100% (16/16) against CaSR peptide 41–69, 31% (5/16) against
114–126, 38% (6/16) against 171–191, and 44% (7/16) against 260–
340 (Table I). Overall, 5/16 (31%), 4/16 (25%), and 7/16 (44%) of
the patient sera showed immunoreactivity against one, two, and
three different epitopes, respectively (Table I). All identified epitopes
resided within the extracellular domain of the CaSR (Supplemental
Fig. 1).
CaSR peptide ELISAs were used to determine CaSR autoanti-
bodies titers against each relevant epitope. The results are
summarized in Table I. Titers ranged from 1:100–1:1000 for
autoantibodies against epitope 41–69, 1:500–1:1000 for epitope
114–126, 1:200–1:1000 for epitope 171–195, and 1:500–1:2000 for
epitope 260–340.
CaSR autoantibodies are epitope specific
The specificity of patient CaSR autoantibodies was analyzed by
preabsorption of purified Abs with CaSR peptides representing
identified epitopes and an unrelated MCHR1 peptide. Any effects
upon CaSR autoantibody binding were then assessed in CaSR
peptide ELISAs. Ab binding was only statistically significantly
The Journal of Immunology 3
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reduced (p , 0.0001) by preabsorption with the CaSR peptide
recognized as the Ab epitope (Fig. 2A–D), indicating there was no
detectable cross-reactivity between CaSR autoantibodies that rec-
ognized different epitopes.
CaSR epitopes are surface expressed
HEK293 cells were transfected with plasmid pcDNA3-CaSR-GPI
and the transfected cells used in flow cytometry analysis with CaSR
autoantibodies purified from APS1 patients. Untransfected HEK293
cells were used as a control. Fluorescence histograms (Fig. 3A–D)
showed a clear increase in the number of fluorescing cells when
CaSR autoantibodies were incubated with HEK293 cells expressing
the CaSR-GPI protein compared with incubation of the same
samples with untransfected cells and compared with preabsorbed
Ab. The results indicated that the recognized epitopes were surface
expressed.
FIGURE 1. CaSR autoantibody binding sites are
located in the extracellular domain. Sera from 16
APS1 patients and 16 healthy controls were eval-
uated at a dilution of 1:100 in ELISAs for auto-
antibodies against CaSR peptides 41–69, 114–126,
171–195, and 260–340. The OD405 value is shown
for each APS1 patient, and control serum and is the
mean of three separate experiments.
Table I. APS1 patient CaSR Ab epitopes, titers, IgG subclass, and functional affinity
APS1 Patient
CaSR Abs against Epitope 41–69 CaSR Abs against Epitope 114–126
Ab Reactivity Ab Titera IgG Subclass
Functional
Affinity (M)b Ab Reactivity Ab Titera IgG Subclass Functional Affinity (M)b
1 + 1:1000 IgG1 7.50 3 1028 2 — — —
2 + 1:500 IgG1 1.00 3 1027 2 — — —
3 + 1:500 IgG1 1.00 3 1027 2 — — —
4 + 1:500 IgG1 1.00 3 1027 2 — — —
5 + 1:1000 IgG1 2.50 3 1027 + 1:500 IgG1 2.00 3 1027
6 + 1:200 IgG1 9.00 3 1028 + 1:500 IgG1 2.00 3 1027
7 + 1:200 IgG1 1.50 3 1027 + 1:500 IgG3 5.00 3 1028
8 + 1:1000 IgG1 3.00 3 1027 2 — — —
9 + 1:100 IgG1 2.00 3 1027 2 — — —
10 + 1:500 IgG1 2.50 3 1027 + 1:500 IgG3 4.00 3 1028
11 + 1:100 IgG1 4.00 3 1028 2 — — —
12 + 1:500 IgG1 1.50 3 1027 2 — — —
13 + 1:200 IgG1 1.50 3 1027 2 — — —
14 + 1:1000 IgG1 2.00 3 1027 2 — — —
15 + 1:1000 IgG1 2.00 3 1027 2 — — —
16 + 1:1000 IgG1 2.00 3 1027 + 1:1000 IgG3
CaSR Abs against Epitope 171–195 CaSR Abs against Epitope 260–340
APS1 Patient Ab Reactivity Ab Titera IgG Subclass
Functional
Affinity (M)b Ab Reactivity Ab Titera IgG Subclass Functional Affinity (M)b
1 2 — — — 2 — — —
2 2 — — — 2 — — —
3 + 1:1000 IgG1 2.50 3 1027 + 1:500 IgG1 1.50 3 1027
4 + 1:500 IgG1 2.50 3 1027 + 1:500 IgG1 1.50 3 1027
5 2 — — — 2 — — —
6 2 — — — 2 — — —
7 2 — — — 2 — — —
8 2 — — — 2 — — —
9 + 1:200 IgG1 8.00 3 1028 + 1:500 IgG1 7.50 3 1028
10 2 — — — 2 — — —
11 2 — — — 2 — — —
12 + 1:500 IgG1 7.50 3 1028 + 1:500 IgG1 7.20 3 1028
13 2 — — — 2 — — —
14 + 1:500 IgG1 3.50 3 1027 + 1:500 IgG1 7.50 3 1028
15 + 1:500 IgG1 3.50 3 1027 + 1:500 IgG1 5.00 3 1028
16 2 — — — + 1:2000 IgG1 1.50 3 1027
aCaSR Ab titers are defined as the APS1 patient serum dilution at which Ab binding could still be detected above the upper limits of normal for the CaSR peptide ELISAs.
bAb functional affinity is given as the concentration of the relevant CaSR peptide that blocked 50% of CaSR Ab binding in CaSR peptide ELISAs.
—, no CaSR Abs to be tested; +, positive for CaSR Ab reactivity in ELISAs; 2, negative for CaSR Ab reactivity in ELISAs.
4 CaSR AUTOANTIBODIES IN APS1
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CaSR autoantibodies are mainly of the IgG1 subclass
CaSR peptide ELISAs were used to analyze the IgG subclass of
patient CaSR autoantibodies. The results indicated that autoan-
tibodies against the CaSR epitopes 41–69, 171–195, and 260–340
were restricted to the IgG1 subclass (Table I). Ab responses against
CaSR epitope 114–126 were of the IgG1 and IgG3 subclasses in
two (patients 5 and 6) and three (patients 7, 10, and 16) patients,
respectively (Table I).
CaSR autoantibodies’ functional affinities
CaSR peptide ELISAs were used to analyze the functional affin-
ities of purified CaSR autoantibodies. The results are summarized
in Table I and show that functional affinities ranged from 1028 to
1027 M, representing the concentration of CaSR peptide that was
required to inhibit Ab binding in CaSR peptide ELISAs by 50%.
CaSR autoantibodies can stimulate the CaSR
Peptide affinity chromatography was used to purify CaSR autoan-
tibodies with different CaSR binding sites from the relevant APS1
patient sera. The effect of CaSR autoantibodies against epitopes
41–69, 114–126, 171–195, and 260–340 on Ca2+ stimulation of the
CaSR was then analyzed by preincubating human embryonic
kidney cells expressing the CaSR (HEK293-CaSR cells) with Ab
samples prior to stimulating with Ca2+ at a range of concentrations
(0.5 to 9.0 mM) (14). Cells without preincubation with Ab and
with preincubation with control IgG were also included. Intra-
cellular IP1 accumulation was measured as the indicator of CaSR
stimulation.
The results are shown in Fig. 4A–E. Preincubation of HEK293-
CaSR cells with CaSR 114–126 autoantibodies from three patients
(patients 5, 7, and 16) and with CaSR 171–195 autoantibodies
from one patient (patient 9) resulted in a statistically significant
increase in IP1 accumulation upon Ca2+ stimulation (at 0.5 and
1.5 mM) compared with Ca2+ stimulation alone; all p values were
,0.0001 (Fig. 4C, 4D). In contrast, preincubation with autoanti-
bodies against CaSR epitopes 41–69 and 260–340 had no detectable
effect upon IP1 accumulation in Ca2+-stimulated HEK293-CaSR
cells; all p values were .0.05 (Fig. 4A, 4B, 4E).
FIGURE 2. CaSR autoantibodies are specific for their binding site. Purified CaSR autoantibody samples were preabsorbed at a nonsaturating dilution with
CaSR peptides 41–69, 114–126, 171–195, 260–340, and MCHR1 control peptide before analysis in CaSR peptide ELISAs along with unabsorbed autoantibody
samples. Ab binding after preabsorption was expressed as a percentage of unabsorbed Ab binding in CaSR peptide ELISAs. The results (mean 6 SD) are
shown for (A) CaSR 41–69 autoantibodies (n = 16) in CaSR peptide 41–69 ELISAs, (B) CaSR 114–126 autoantibodies (n = 5) in CaSR peptide 114–126
ELISAs, (C) CaSR 171–195 autoantibodies (n = 6) in CaSR peptide 171–195 ELISAs, and (D) CaSR 260–340 autoantibodies (n = 7) in CaSR peptide 260–340
ELISAs. Ab binding was reduced significantly (p , 0.0001) only when preabsorption was with the CaSR peptide representing the Ab epitope.
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CaSR autoantibodies can reduce PTH secretion
With respect to epitopes 41–69 and 114–126, the rat CaSR shows
100% amino acid homology with the human CaSR. In the case of
epitope 171–195, 24 of the 25 aa residues are identical in the rat
and human receptors. Therefore, to test whether CaSR autoanti-
bodies against epitopes 41–69, 114–126, 171–195 could affect PTH
secretion, rat parathyroid PTH-C1 cells were preincubated with
Ab samples prior to calcium stimulation. Cells without preincubation
with Ab were also included as a control. Secreted PTH was then
measured in cell supernatants.
The results showed that preincubation of PTH-C1 cells with CaSR
114–126 autoantibodies purified from three patients (patients 5, 7,
and 16) reduced PTH secretion by 72, 70, and 66%, respectively,
when compared with PTH secretion from PTH-C1 cells not pre-
incubated with Ab (Fig. 5A). Likewise, pretreatment with CaSR
171–195 autoantibodies from one patient (patient 9) reduced PTH
secretion by 69% (Fig. 5B). In these four cases, the reduction in
PTH secretion was statistically significant; all p values were,0.0001
(Fig. 5A, 5B). In contrast, preincubation with any of the patient
autoantibodies against CaSR epitope 41–69 did not reduce the
secretion of PTH; all p values were .0.05 (Fig. 5A, 5B).
Discussion
To understand more fully the potential role for CaSR autoanti-
bodies in APS1, the aim of the current study was to characterize
specificity, functional affinity, IgG subclass, and effects on CaSR
activity of CaSR autoantibodies identified in relation to their
epitopes. Initially, CaSR autoepitopes were identified at amino acid
residues 41–69 (all patients), 114–126 (31% of patients), 171–195
(38% of patients), and 260–340 (44% of patients), all found in the
N-terminal of the receptor’s extracellular domain. Although the
epitope domain at residues 260–340 constituted a novel CaSR Ab
binding site, the remaining three epitopes were reported previ-
ously (16). Of note, the CaSR peptide 260–340 was identified after
panning experiments with only one patient IgG (patient 4), and it
then represented just 10% of the recovered sequences. It is pos-
sible that the CaSR peptide 260–340 was poorly expressed in the
phage-display system, so had less chance of being recovered
during the rounds of enrichment. As B cell epitopes are generally
up to 20 aa (18), those represented by aa 260–340 (81 residues)
and 41–69 (38 residues) require finer mapping experiments to
determine the exact Ab binding sites.
One aim of the current study was to determine whether auto-
antibodies against the CaSR in APS1 patients were able to mod-
ulate the function of the receptor because such Abs are more likely
to have a direct role in disease pathogenesis than Abs that have only
binding activity. For example, thyroid-stimulating Abs activate
the TSH receptor and elicit hyperthyroidism in Graves disease by
mimicking the binding of TSH, and Abs directed against the
acetylcholine receptor block the acetylcholine-binding site and
provoke accelerated receptor degradation causing myasthenia
FIGURE 3. Flow cytometry analysis of CaSR autoantibodies. Cells were incubated with purified CaSR autoantibodies. The mean fluorescent intensity of the cell
population was determined by flow cytometry following the addition of FITC-conjugated secondary Ab. Representative fluorescence histograms with untransfected
HEK293 cells (thin line) and HEK293 CaSR-GPI–expressing cells (thick line) are shown for (A) CaSR 114–126 autoantibody from patient 5, (B) preabsorbed CaSR
114–126 autoantibody from patient 5, (C) CaSR 171–195 autoantibody from patient 9, and (D) preabsorbed CaSR 171–195 autoantibody from patient 9.
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FIGURE 4. CaSR autoantibodies can stimulate the CaSR. HEK293-CaSR cells were preincubated with purified Ab against CaSR epitopes 41–69, 114–
126, 171–195, and 260–340 or control IgG at a 1:100 dilution prior to stimulation with Ca2+ at 0.0, 0.5, 1.5, 3.0, 6.0, and 9.0 mM. Cells without Ab
preincubation and with preincubation with control IgG were also included. Inositol-1-phosphate (IP1) accumulation in the cell lysates was measured in
duplicate in an IP-One ELISA, and IP1 accumulation was expressed as percentage inhibition of IP1–HRP binding. All Ab samples were analyzed in six
separate experiments. The mean IP1 accumulation 6SD is shown for (A) CaSR autoantibodies against epitope 41–69, (B) CaSR autoantibodies against
epitope 41–69, (C) CaSR autoantibodies against epitope 114–126, (D) CaSR autoantibodies against epitope 171–195, and (E) CaSR autoantibodies against
epitope 260–340. Preincubation of HEK293-CaSR cells with CaSR 114–126 autoantibodies from three patients (patients 5, 7, and 16), and CaSR 171–195
autoantibodies from one patient (patient 9) resulted in a significant increase (p , 0.0001) in IP1 accumulation upon Ca2+ stimulation (at 0.5 and 1.5 mM)
compared with Ca2+ stimulation alone. IC50 values were 1.05–1.09 and 1.10 mM for the CaSR 114–126 and 171–195 autoantibodies, respectively.
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gravis (19). In the case of the CaSR, autoantibody-induced acti-
vation could result in low levels of PTH and the resultant hypo-
parathyroidism that is associated with APS1. To date, only a small
number of patients with hypoparathyroidism has been identified
who also have CaSR-activating autoantibodies that could poten-
tially reduce PTH-secretion. First, sera from two patients with
idiopathic hypoparathyroidism inhibited PTH release from human
parathyroid cells (13). Second, IgG from two patients with APS1,
both of whom had hypoparathyroidism, activated the CaSR
expressed in HEK293 cells (14). In the current study, 4 of 16 (25%)
patients had CaSR autoantibodies that stimulated the receptor
expressed in HEK293-CaSR cells and suppressed PTH secre-
tion from PTH-C1 cells. In three cases, the CaSR autoantibodies
recognized epitope 114–126 and, in one case, the 171–195 Ab
binding site. There were no apparent differences in the clinical details
of patients with or without functional autoantibodies to either of the
two determinants on the CaSR. However, there is potential for het-
erogeneity within the autoantibody populations that recognize these
two epitopes, and this may distinguish functional autoantibodies
that are associated with particular clinical characteristics.
The epitope constituting aa 114–126 overlaps with the loop 2
domain of the CaSR (20). Point mutations in or deletions of this
part of the receptor increase the sensitivity of the CaSR to Ca2+
and result in autosomal dominant hypoparathyroidism (20, 21).
From these observations, it has been suggested that loop 2 may
have an important role in maintaining the inactive state of the
CaSR involving disulphide links through cysteine residues C129
and C131. Indeed, mutations involving either of these amino
acid residues results in autosomal dominant hypoparathyroidism
(www.casrdb.mcgill.ca). Ab binding to epitopes that are found
within loop 2 could either inhibit or activate the CaSR, depending
on whether Ab binding favored the active or inactive state of the
receptor, respectively. The Ab binding site at aa 171–195 is of
particular interest because site-directed mutagenesis and molecu-
lar models have indicated that some of these residues (S147, S170,
and D190) form part of a binding site for Ca2+ that is found in the
crevice between the two lobes of each receptor monomer (20, 22,
23). Therefore, binding of an Ab to this area of the CaSR could
disrupt the interaction of Ca2+ with this Ca2+ binding site.
Similar to previous studies on IgG subclass determination in
autoimmune disease (24, 25), CaSR autoantibodies against all
identified epitopes were mainly of the IgG1 subclass. In a minority
of APS1 patients, autoantibodies against epitope 114–126 were
of the IgG3 subclass. CaSR autoantibodies of the IgG2 and IgG4
subclasses were not identified. This is the first report, to our
knowledge, regarding IgG subclass for autoantibodies against the
CaSR in patients with hypoparathyroidism in the context of APS1,
although CaSR autoantibodies exclusively of the IgG4 subtype
have been found in a patient with autoimmune hypocalciuric hy-
percalcemia (11). Notably, both IgG1 and IgG3 subclass Abs can
induce cell-mediated effector mechanisms and have the capacity
to activate complement (26, 27). However, these pathomechan-
isms require investigation in relation to autoantibodies against
the CaSR.
In patients with CaSR-stimulating autoantibodies, it could be that
their hypoparathyroidism is caused by autoantibody activity against
the CaSR instead of parathyroid gland destruction. This would be
analogous to the action of pathogenic autoantibodies against the
thyroid-stimulating hormone receptor in Graves disease (19). How-
ever, there were no data on whether the parathyroid of the APS1
patients with CaSR autoantibodies did or did not have lymphocyte
infiltration. An important implication of the present results is that
although the majority of APS1 patients do not have CaSR-stimulating
Abs, there may be a small but substantial minority of patients in
whom the hypoparathyroid state is the result of functional suppres-
sion of the parathyroid glands rather than their irreversible destruc-
tion. The documentation of the inactivating CaSR autoantibodies in
autoimmune hypocalciuric hypercalcaemia proves that the presence
of CaSR autoantibodies need not produce destruction of the para-
thyroid glands (9). In addition, our earlier demonstration of the
presence of activating autoantibodies to the CaSR in one patient with
transient hypoparathyroidism as well as in a second hypoparathyroid
patient with a morphologically intact parathyroid gland despite many
years of hypoparathyroidism proves that activating Abs also need not
irreversibly destroy the parathyroids (13).
In such cases, it is possible that a calcilytic CaSR inhibitor might
be of diagnostic and/or therapeutic utility. Because such agents
FIGURE 5. CaSR autoantibodies can reduce PTH secretion. Rat para-
thyroid PTH-C1 cells were preincubated with purified autoantibodies against
CaSR epitopes 41–69, 114–126, or 171–195 at a 1:100 dilution prior to
stimulation with 1.5 mM Ca2+. PTH-C1 cells without preincubation with Ab
were included as a control. PTH secretion was measured in duplicate in cell
supernatants with a Rat Intact PTH ELISA Kit, and the PTH levels were
expressed as picograms per milliliter. Each patient Ab sample was analyzed
in six separate experiments. The mean (6SD) PTH concentration is shown
for (A) CaSR autoantibodies against epitopes 114–126 and 41–69 purified
from patients 5, 6, 7, 10, and 16 and (B) CaSR autoantibodies against epi-
topes 171–195 and 41–69 purified from patients 3, 4, 9, 12, 14, and 15.
Preincubation of PTH-C1 cells with CaSR 114–126 autoantibodies from
three patients (patients 5, 7, and 16), and CaSR 171–195 autoantibodies from
one patient (patient 9) resulted in a significant reduction (*p , 0.0001) in
PTH secretion upon Ca2+ stimulation compared with Ca2+ stimulation alone.
n.s., not statistically significant.
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acutely stimulate PTH secretion by blocking the inhibitory effect of
calcium on the CaSR, demonstrating a PTH response in a hypo-
parathyroid subject administered a calcilytic could document the
presence of residual functioning parathyroid tissue. Moreover, if
such functioning tissue were present, the calcilytic might be of
therapeutic utility if it were able to block the suppressive effect of
the Ab on parathyroid function.
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